https://orcid.org/0000-0001-8518-5750
Abstract
The impact of glucocorticoids, comorbidities, and immunosuppressive therapies on Pneumocystis jirovecii pneumonia (PJP) risk remains understudied, and prophylaxis is underutilized. Among U.S. adults in TriNetX prescribed glucocorticoids for ≥2 weeks in TriNetX, 44.6% received >20mg prednisone equivalents/day. Prophylaxis rates were low, with higher glucocorticoid doses associated with lower prophylaxis odds.
Glucocorticoids, Immunosuppressive Agents, Biological Therapy, Immunomodulation, Pneumonia, Pneumocystis, Opportunistic Infections
Accepted manuscriptsAccepted manuscripts are PDF versions of the author’s final manuscript, as accepted for publication by the journal but prior to copyediting or typesetting. They can be cited using the author(s), article title, journal title, year of online publication, and DOI. They will be replaced by the final typeset articles, which may therefore contain changes. The DOI will remain the same throughout.
This content is only available as a PDF.
© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
